Cynata Therapeutics Receives Clearance to Proceed to Second Group in Phase 1/2 Kidney Transplant Trial; Shares Jump 10%

MT Newswires Live

Dec 04, 2025

Cynata Therapeutics (ASX:CYP) said an independent data and safety monitoring board completed a planned review of the first group of patients treated in the phase 1/2 NEREID kidney transplant trial, which did not raise safety concerns for its CYP-001 therapy candidate, granting clearance to proceed to the second group, according to a Thursday Australian bourse filing.

The first group of patients in the trial each received a single intravenous infusion of the candidate around six weeks after receiving a kidney transplant, in addition to standard treatment. There were no episodes of kidney transplant rejection in this group.

The trial is evaluating CYP-001 as a potential treatment to reduce reliance on long-term immunosuppressant drugs in kidney transplant recipients. The second group in the trial will involve another three patients, each of whom will receive two infusions of CYP-001, in addition to standard treatment.

The firm's shares jumped 10% in recent trading on Thursday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2588719040"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2588719040\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2588719040?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-04 10:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588719040","market":"sg","top_or_hot":-1,"title":"Cynata Therapeutics Receives Clearance to Proceed to Second Group in Phase 1/2 Kidney Transplant Trial; Shares Jump 10%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CYP.AU\">Cynata Therapeutics</a> (ASX:CYP) said an independent data and safety monitoring board completed a planned review of the first group of patients treated in the phase 1/2 NEREID kidney transplant trial, which did not raise safety concerns for its CYP-001 therapy candidate, granting clearance to proceed to the second group, according to a Thursday Australian bourse filing.</p><p>The first group of patients in the trial each received a single intravenous infusion of the candidate around six weeks after receiving a kidney transplant, in addition to standard treatment. There were no episodes of kidney transplant rejection in this group.</p><p>The trial is evaluating CYP-001 as a potential treatment to reduce reliance on long-term immunosuppressant drugs in kidney transplant recipients. The second group in the trial will involve another three patients, each of whom will receive two infusions of CYP-001, in addition to standard treatment.</p><p>The firm's shares jumped 10% in recent trading on Thursday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cynata Therapeutics Receives Clearance to Proceed to Second Group in Phase 1/2 Kidney Transplant Trial; Shares Jump 10%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCynata Therapeutics Receives Clearance to Proceed to Second Group in Phase 1/2 Kidney Transplant Trial; Shares Jump 10%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-04 10:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CYP.AU\">Cynata Therapeutics</a> (ASX:CYP) said an independent data and safety monitoring board completed a planned review of the first group of patients treated in the phase 1/2 NEREID kidney transplant trial, which did not raise safety concerns for its CYP-001 therapy candidate, granting clearance to proceed to the second group, according to a Thursday Australian bourse filing.</p><p>The first group of patients in the trial each received a single intravenous infusion of the candidate around six weeks after receiving a kidney transplant, in addition to standard treatment. There were no episodes of kidney transplant rejection in this group.</p><p>The trial is evaluating CYP-001 as a potential treatment to reduce reliance on long-term immunosuppressant drugs in kidney transplant recipients. The second group in the trial will involve another three patients, each of whom will receive two infusions of CYP-001, in addition to standard treatment.</p><p>The firm's shares jumped 10% in recent trading on Thursday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2588719040","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588719040","pubTimestamp":1764815349,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Cynata Therapeutics  said an independent data and safety monitoring board completed a planned review of the first group of patients treated in the phase 1/2 NEREID kidney transplant trial, which did not raise safety concerns for its CYP-001 therapy candidate, granting clearance to proceed to the second group, according to a Thursday Australian bourse filing.The first group of patients in the trial each received a single intravenous infusion of the candidate around six weeks after receiving a kidney transplant, in addition to standard treatment. There were no episodes of kidney transplant rejection in this group.The trial is evaluating CYP-001 as a potential treatment to reduce reliance on long-term immunosuppressant drugs in kidney transplant recipients. The second group in the trial will involve another three patients, each of whom will receive two infusions of CYP-001, in addition to standard treatment.The firm's shares jumped 10% in recent trading on Thursday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LENZ":"Therapeutics","BK7067":"生物科技","CYP.AU":"CYNATA THERAPEUTICS LTD","BK7508":"医药生物股","BK7501":"新冠治疗股","BK4007":"制药","BK4539":"次新股"},"translate_title":"Cynata Therapeutics获得进入1/2期肾移植试验第二组的许可；股价上涨10%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CYP.AU":1,"LENZ":1.5},"content_text":"Cynata Therapeutics (ASX:CYP) said an independent data and safety monitoring board completed a planned review of the first group of patients treated in the phase 1/2 NEREID kidney transplant trial, which did not raise safety concerns for its CYP-001 therapy candidate, granting clearance to proceed to the second group, according to a Thursday Australian bourse filing.The first group of patients in the trial each received a single intravenous infusion of the candidate around six weeks after receiving a kidney transplant, in addition to standard treatment. There were no episodes of kidney transplant rejection in this group.The trial is evaluating CYP-001 as a potential treatment to reduce reliance on long-term immunosuppressant drugs in kidney transplant recipients. The second group in the trial will involve another three patients, each of whom will receive two infusions of CYP-001, in addition to standard treatment.The firm's shares jumped 10% in recent trading on Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}